R William Chong1, Vijaya Vasudevan2, Jeffrey Zuber3, Solomon S Solomon4. 1. Division of Endocrinology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 2. Division of Endocrinology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Medicine (Endocrinology) and Research Service, Veterans Affairs Medical Center, Memphis, Tennessee. 3. Department of Preventive Medicine, College of Medicine, Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee. 4. Division of Endocrinology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Medicine (Endocrinology) and Research Service, Veterans Affairs Medical Center, Memphis, Tennessee. Electronic address: ssolomon@uthsc.edu.
Abstract
OBJECTIVE: Prostate cancer and type 2 diabetes mellitus (DM2) are both common diseases found in the elderly male population. The diabetic drug, metformin, has been shown to have antineoplastic properties and demonstrated better treatment outcomes when used as adjuvant therapy in patients with breast cancer. The hormonally-sensitive cancer analogous to breast cancer in men is prostate cancer. We investigated improved survival, lower risks of recurrences, and lower, more stable levels of prostate-specific antigen (PSA) in patients with DM2 along with prostate cancer on metformin. METHODS: Patients with prostate cancer along with DM2 who remained on metformin were compared with controls who were not on metformin matched by age, weight, race and Gleason score cancer staging. The endpoints of our study included final PSA values, number of recurrences, metastases and number living for each group. RESULTS: There were significantly fewer deaths (23% versus 10%), fewer recurrences (15% versus 8%), fewer metastases (5% versus 0%) and fewer secondary cancers (17% versus 6%) in the metformin group (P < 0.004). The final PSA value was lower in the metformin-treated group with a result approaching significance (P = 0.067). The primary treatments for prostate cancer (ie, surgery, radiation and androgen depletion) were found to be comparable in both the groups. CONCLUSIONS: Our retrospective study shows that adjuvant metformin therapy leads to a better prognosis in prostate cancer. Not only are PSA levels controlled for several years but also there are significantly fewer cancer recurrences in metformin-treated patients. Overall, these results are promising and should be followed up with a prospective study to assess long-term survival. Published by Elsevier Inc.
OBJECTIVE:Prostate cancer and type 2 diabetes mellitus (DM2) are both common diseases found in the elderly male population. The diabetic drug, metformin, has been shown to have antineoplastic properties and demonstrated better treatment outcomes when used as adjuvant therapy in patients with breast cancer. The hormonally-sensitive cancer analogous to breast cancer in men is prostate cancer. We investigated improved survival, lower risks of recurrences, and lower, more stable levels of prostate-specific antigen (PSA) in patients with DM2 along with prostate cancer on metformin. METHODS:Patients with prostate cancer along with DM2 who remained on metformin were compared with controls who were not on metformin matched by age, weight, race and Gleason score cancer staging. The endpoints of our study included final PSA values, number of recurrences, metastases and number living for each group. RESULTS: There were significantly fewer deaths (23% versus 10%), fewer recurrences (15% versus 8%), fewer metastases (5% versus 0%) and fewer secondary cancers (17% versus 6%) in the metformin group (P < 0.004). The final PSA value was lower in the metformin-treated group with a result approaching significance (P = 0.067). The primary treatments for prostate cancer (ie, surgery, radiation and androgen depletion) were found to be comparable in both the groups. CONCLUSIONS: Our retrospective study shows that adjuvant metformin therapy leads to a better prognosis in prostate cancer. Not only are PSA levels controlled for several years but also there are significantly fewer cancer recurrences in metformin-treated patients. Overall, these results are promising and should be followed up with a prospective study to assess long-term survival. Published by Elsevier Inc.
Entities:
Keywords:
Metformin; Prognosis; Prostate cancer; Prostate specific antigen; Type 2 diabetes mellitus
Authors: J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons Journal: Science Date: 1997-03-28 Impact factor: 47.728
Authors: Ryan J O Dowling; Mahvash Zakikhani; I George Fantus; Michael Pollak; Nahum Sonenberg Journal: Cancer Res Date: 2007-11-15 Impact factor: 12.701
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Alicia Bort; Sergio Quesada; Ágata Ramos-Torres; Marta Gargantilla; Eva María Priego; Sophie Raynal; Franck Lepifre; Jose M Gasalla; Nieves Rodriguez-Henche; Ana Castro; Inés Díaz-Laviada Journal: Sci Rep Date: 2018-03-12 Impact factor: 4.379
Authors: Le Tang; Fang Wei; Yingfen Wu; Yi He; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Hao Deng; Ke Cao; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng Journal: J Exp Clin Cancer Res Date: 2018-04-23